PLASMA-FREE THYROXINE (FT4) CONCENTRATIONS DURING HEMODIALYSIS IN PATIENTS WITH CHRONIC-RENAL-FAILURE - EFFECTS OF PLASMA NONESTERIFIED FATTY-ACIDS ON FT4 MEASUREMENT
M. Nishikawa et al., PLASMA-FREE THYROXINE (FT4) CONCENTRATIONS DURING HEMODIALYSIS IN PATIENTS WITH CHRONIC-RENAL-FAILURE - EFFECTS OF PLASMA NONESTERIFIED FATTY-ACIDS ON FT4 MEASUREMENT, Endocrine journal, 43(5), 1996, pp. 487-493
Plasma free T4 (FT4) concentrations could be increased during hemodial
ysis in patients with chronic renal failure (CRF) because an increase
in non-esterified fatty acids (NEFA) could interfere with the binding
of T4 to thyroxine-binding globulin. To evaluate the effect of hemodia
lysis on the FT4 concentration in patients with CRF, we measured the F
T4 in 39 patients with CRF by four assay methods including equilibrium
dialysis, the I-125-T4 analog method and enzyme immunoassay. The addi
tion of the fatty acid sodium oleate to normal pooled sera led to a ma
rked increase in FT4 as measured by equilibrium dialysis (Mode! FT4).
A moderate increase in the serum FT4 concentration also was observed w
ith an IMX enzyme immunoassay kit, whereas the Coat-A-Count analog met
hod demonstrated no interference by sodium oleate. The mean serum FT4
prior to hemodialysis measured by equilibrium dialysis did not differ
significantly from that in the normal control, although those measured
by analog methods (Coat-A-Count and Amerlex) and IMX were subnormal.
The FT4 by IMX were albumin-dependent, and the values decreased as the
samples were serially diluted, but Model FT4 was not affected by the
albumin level or the serial dilution. FT4 by Model FT4 showed a marked
increase beginning 10 min after the start of dialysis, and it correla
ted well with the plasma concentration of NEFA and the NEFA/albumin mo
lar ratio. The other three assay methods, including one which is not a
ffected by NEFA, did not show a change in FT4 at 10 min, but a signifi
cant increase of 11 to 17% was observed by the end of dialysis. The TS
H concentration decreased significantly during hemodialysis. These dat
a suggest that (1) the low serum FT4 in hemodialysis patients measured
by some immunoassay methods may be an underestimation due to the low
albumin level; (2) FT4 actually increases during hemodialysis due to t
he actual increase in NEFA, although the marked increase in FT4 during
hemodialysis as measured by equilibrium dialysis is an overestimation
due to the in vitro generation of NEFA; and (3) one should beware of
abberations in thyroid hormone parameters during hemodialysis and pote
ntial complications.